Company / Return on Equity (ROE)
Erasca, Inc. Return on Equity (ROE) History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-38.2%
FY2024
5-year range
-59.0% / -26.9%
FY2021-FY2024
Trend
+3.3%
vs FY2023
Sector context
#116 of 190
Health Care
What the data says
Erasca, Inc. reports negative total equity of -38.2% in FY2024. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-38.2% in FY2024 with a 3-year CAGR of -11.3%.
Improved from -59.0% to -38.2% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -11.3pp
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
#116 of 190 in Health CareTop 61% of 190This company -38.2% Sector average -50.4%
▼
+24.3% above sector average
Key checks
Key Insights
- In FY2024, return on equity (roe) increased 3.3% year-over-year.
- Currently 12.3pp above the Health Care sector average.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -38.2% | +3.3% |
| FY2023 | -39.5% | +33.0% |
| FY2022 | -59.0% | -119.2% |
| FY2021 | -26.9% | - |
| FY2020 | - | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026